Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Platelet aggregation, thrombosis formation, and inflammation are the main causes of cardiac injury during PCI.

Vitamin D plays a key role in the cardiovascular system by exerting antiplatelet, anticoagulant, and anti-inflammatory properties.

Who Took Part

The abstract describes 99 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

In a randomized clinical trial, 99 patients admitted for elective PCI were randomized into vitamin D (n = 52) and control (n = 47) groups.

How the Study Was Run

The design is described as randomized, single-blind and pilot.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

In this single-blind Vitamin D, K2, Magnesium and Zinc study one party knew the assignments and the other did not.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

What Was Measured

PubMed files the paper under topics including C-Reactive Protein, Coronary Artery Disease, Creatine Kinase, MB Form, Heart Injuries, Percutaneous Coronary Intervention, Pilot Projects and Vitamin D.

Author keywords: CK-MB, cTnI, hs-CRP and periprocedural myocardial injury.

What This Means in Plain Language

The paper is a randomized, single-blind and pilot study of Vitamin D, K2, Magnesium and Zinc in 99 patients.

The publication is from 2018 (Journal of clinical pharmacology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.